LLY : Insider Transactions for Eli Lilly & Co | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

Eli Lilly & Co (LLY)

$909.04

7.78 (0.86%) as of 4:30 Thu 6/27

Download

Exchange:

New York Stock Exchange

Security Type:

Common

Shares Out:

956,580,000

Market Cap:

869.57(B)

Last Volume:

1,947,382

Avg Vol:

3,268,697

52 Week Range:

$434.7 - $909.04

Level I Sector:

Health Care

Level II Sector:

Drugs

Level III Sector:

Drug Manufacturers - Major

Member Indexes:

	S&P COMPOSITE 1500		NYSE COMPOSITE
	S&P 500

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : 720

Guru Rank Value : 1.4

Guru Occurances : 2


6 Months 1 Year 2 Year

Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	0	656
Total Buy Value	$0	$0	$0	$199,549
Total People Bought	0	0	0	1
Total Buy Transactions	0	0	0	1
Total Shares Sold	1,520,577	2,391,327	3,815,444	6,318,238
Total Sell Value	$1,284,658,855	$1,892,909,435	$2,147,483,647	$2,147,483,647
Total People Sold	3	3	4	6
Total Sell Transactions	18	31	51	93
End Date	2024-03-30	2023-12-28	2023-06-29	2022-06-29

Adjust Filter Settings

Records found: 1436

Page 40 of 58

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

Lilly Endowment Inc

10% Owner

– – •

2017-07-31

4

S

$83.08

$18,279,478

D/D

(220,000)

124,045,804

-

Director

– • –

2017-07-17

4

A

$83.64

$9,702

D/D

116

2,772

-

Director

– • –

2017-07-17

4

A

$83.64

$10,957

D/D

131

36,470

-

Lilly Endowment Inc

10% Owner

– – •

2017-06-22

4

S

$84.43

$17,730,720

D/D

(210,000)

124,265,804

-

Lilly Endowment Inc

10% Owner

– – •

2017-06-20

4

S

$83.05

$17,855,363

D/D

(215,000)

124,475,804

-

Director

– • –

2017-06-19

4

A

$82.34

$10,951

D/D

133

36,339

-

Director

– • –

2017-06-19

4

A

$82.34

$9,634

D/D

117

2,656

-

President & CEO

• • –

2017-06-14

4

GD

$0.00

$0

D/D

25

107,433

-

Barnes Melissa S

Chief Eth/Cmpl Ofcr & SVP, ERM

• – –

2017-06-12

4

S

$80.78

$153,482

D/D

(1,900)

14,041

-

Harrington Michael J

Senior VP and General Counsel

• – –

2017-06-09

4

AS

$79.97

$1,825,955

D/D

(22,833)

62,056

-

Lechleiter John C

former director

– – –

2017-05-25

4

GA

$0.00

$0

I/I

387,058

436,160

-

Lechleiter John C

former director

– – –

2017-05-25

4

GD

$0.00

$0

D/D

387,058

436,161

-

Simmons Jeffrey N

SVP&Pres. Elanco Animal Health

• – –

2017-05-22

4

GD

$0.00

$0

D/D

6,390

118,132

-

Director

– • –

2017-05-15

4

A

$80.30

$10,921

D/D

136

35,980

-

Director

– • –

2017-05-15

4

A

$80.30

$9,636

D/D

120

2,525

-

President & CEO

• • –

2017-05-05

4

GD

$0.00

$0

D/D

357

107,076

-

Lechleiter John C

former director

– – –

2017-05-04

4

GD

$0.00

$0

D/D

11,072

823,219

-

Conterno Enrique A

SVP&Pres, LillyDiab & LillyUSA

• – –

2017-05-04

4

S

$82.76

$2,069,000

D/D

(25,000)

114,217

-

Director

– • –

2017-04-17

4

A

$82.38

$9,638

D/D

117

2,405

-

Director

– • –

2017-04-17

4

A

$82.38

$10,957

D/D

133

35,844

-

Senior VP, Global QualityOffic

• – –

2017-04-01

3

IO

$0.00

$0

I/I

0

1,935

-

Senior VP, Global QualityOffic

• – –

2017-04-01

3

IO

$0.00

$0

D/D

0

14,493

-

Lilly Endowment Inc

10% Owner

– – •

2017-03-30

4

S

$84.67

$17,781,540

D/D

(210,000)

124,690,804

-

Director

– • –

2017-03-20

4

A

$83.73

$9,629

D/D

115

2,288

-

Director

– • –

2017-03-20

4

A

$83.73

$10,885

D/D

130

35,711

-

1436 Records found	Previous 40 41 42 43 44 45 46 47 48 49 Next	Page 40 of 58

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.